Eledon Pharmaceuticals (ELDN) Share-based Compensation (2013 - 2026)

Eledon Pharmaceuticals (ELDN) has 14 years of Share-based Compensation data on file, last reported at $2.2 million in Q1 2026.

• Quarterly Share-based Compensation fell 23.11% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.8 million (down 31.51% YoY) and the FY2025 annual result came in at $10.5 million, down 20.36% from the prior year.
• Share-based Compensation declined to $2.2 million in Q1 2026, from $2.5 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $6.6 million in Q4 2024 to a low of $1.4 million in Q1 2023.
• A 5-year average of $2.4 million and a median of $2.2 million in 2022 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2024 — Share-based Compensation soared 284.91% — and 2025, when it plunged 62.55%.
• Tracing ELDN's Share-based Compensation over 5 years: stood at $1.5 million in 2022, then advanced by 16.01% to $1.7 million in 2023, then soared by 284.91% to $6.6 million in 2024, then sank by 62.55% to $2.5 million in 2025, then slipped by 10.67% to $2.2 million in 2026.
• The last three Share-based Compensation figures came in at $2.2 million (Q1 2026), $2.5 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.